share_log

Altimmune | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-TIAA-CREF Investment Management, LLC(2.88%),Teachers Advisors, LLC(0.32%), etc.

SEC announcement ·  Feb 14 11:37
Summary by Moomoo AI
On December 31, 2023, Altimmune Inc., a biopharmaceutical company, was the subject of a Schedule 13G filing with the Securities and Exchange Commission (SEC), indicating changes in ownership by significant investors. The filing was made by three investment management firms: Nuveen Asset Management, LLC (NAM), TIAA-CREF Investment Management, LLC (TCIM), and Teachers Advisors, LLC (TAL), all organized under the laws of Delaware. According to the amendment, NAM reported ownership of 6,679 shares, TCIM reported 1,549,364 shares, and TAL reported 171,273 shares of Altimmune's common stock. Collectively, these firms now beneficially own 1,727,316 shares, representing 3.21% of the company's class of common stock. The filing, dated February 14, 2024, asserts that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of Altimmune Inc.
On December 31, 2023, Altimmune Inc., a biopharmaceutical company, was the subject of a Schedule 13G filing with the Securities and Exchange Commission (SEC), indicating changes in ownership by significant investors. The filing was made by three investment management firms: Nuveen Asset Management, LLC (NAM), TIAA-CREF Investment Management, LLC (TCIM), and Teachers Advisors, LLC (TAL), all organized under the laws of Delaware. According to the amendment, NAM reported ownership of 6,679 shares, TCIM reported 1,549,364 shares, and TAL reported 171,273 shares of Altimmune's common stock. Collectively, these firms now beneficially own 1,727,316 shares, representing 3.21% of the company's class of common stock. The filing, dated February 14, 2024, asserts that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of Altimmune Inc.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more